LIPOCINE INC. overview

Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference PR Newswire SALT LAKE CITY, Sept. 19, 2023 SALT LAKE CITY , Sept. 19, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that Dr. Mahesh Patel, President and Chief Executive Officer, will present and meet with investors at the 2023 Cantor Fitzgerald Global Healthcare Conference to take place September 26th to September...

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023 PR Newswire SALT LAKE CITY, Aug. 10, 2023 SALT LAKE CITY , Aug. 10, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced financial results for the second quarter and six months ended June 30, 2023 , and provided a corporate update. Clinical Program Highlights Neuroactive Steroids Lipocine announced positive topline...

LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis PR Newswire SALT LAKE CITY, July 27, 2023 Met primary endpoint: treatment with LPCN 1148 increased L3 skeletal muscle index (L3-SMI) relative to placebo (P <0.01) Fewer hepatic encephalopathy (HE) events of grade >1 in the LPCN 1148 treatment arm relative to placebo (P < 0.05) More patients on LPCN 1148 reported symptom improvement compared to placebo (P < 0.05) LPCN 1148 was well-tolerated, with AE rates and severities...

Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference PR Newswire SALT LAKE CITY, June 14, 2023 SALT LAKE CITY , June 14, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to develop differentiated products, today announced that Dr. Mahesh Patel , President and Chief Executive Officer, will present virtually and meet with investors at the H.C....

Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023 PR Newswire SALT LAKE CITY, June 7, 2023 Phase 2 proof-of-concept study of LPCN 1148 in male cirrhotic patients with sarcopenia is fully enrolled with topline 24-week results expected mid-2023 SALT LAKE CITY , June 7, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary technology platform to develop...

Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression PR Newswire SALT LAKE CITY, May 16, 2023 Identified dosing regimen that enables reliance on a single confirmatory pivotal pharmacokinetic (PK) study to establish efficacy for postpartum depression (PPD) and support NDA submission LPCN 1154 treatment was well-tolerated with no hypoxia or sedation-related adverse events Lipocine plans to initiate the...

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023 PR Newswire SALT LAKE CITY, May 11, 2023 SALT LAKE CITY , May 11, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to develop differentiated products, today announced financial results for the first quarter ended March 31, 2023 , and provided a corporate update. First Quarter Highlights...

First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154 PR Newswire SALT LAKE CITY, April 3, 2023 LPCN 1154 is an oral formulation of brexanolone in development for the rapid relief of postpartum depression (PPD) Topline study results expected in H1 2023 SALT LAKE CITY , April 3, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to...